‘Sec. 2. 17-A MRSA §1101, sub-§16-A, ¶¶ I to O are enacted to read:
I. 4 - methylethcathinone, 4-MEC;
J. Butylone;
K. Eutylone;
L. Pentedrone;
M. Pentylone;
N. 2, 5 - dimethoxy-4-ethylphenethylamine; or
O. A derivative of cathinone, including any compound, material, mixture, preparation or other product, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl or thiophene ring systems, whether or not the compound is further modified in any of the following ways:
(1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substitutents;
(2) By substitution at the 3-position with an acyclic alkyl substituent; or
(3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
This paragraph does not include a drug listed in section 1102 or a drug approved by the United States Food and Drug Administration.’